Dedagroup Stealth Acquires Zedonk
Dedagroup Stealth, the tech company behind more than 60% of Italy’s best-known global fashion brands, has acquired Zedonk, the company relied on by more than 650 small fashion businesses.
Until now, smaller brands and start-ups had no access to a single, integrated solution for managing the entire product life cycle, from initial design and production, right through to multichannel distribution in retail, wholesale, marketplaces and social commerce channels, and in addition they had no access to an Enterprise Resource Planning (ERP) technology to support rapid international growth. The acquisition of Zedonk by Dedagroup Stealth fills this market gap.
Dedagroup Stealth is one of only a handful of international companies with a wide range of software solutions for the efficient and flexible management of all the production and distribution processes for fashion products across multiple channels, which has given it leadership among large and medium-sized brands.
Now, with Zedonk, Dedagroup Stealth will be a unique partner for smaller fashion companies, from the very beginning of their growth trajectory right through to international expansion.
Zedonk enables brands in their emerging phase as well as those who are established, but want to accelerate their digital transformation journeys. Its solutions include design and production management, stock inventory, purchase orders, style management as well as customer and supplier relations, with all data managed and protected in the Cloud.
As well as complementary technologies, the two companies now have a significant footprint in the UK through new headquarters in London where Dedagroup Stealth consultants already on the ground will join the Zedonk team.
Marcia Lazar, Co-founder of Zedonk, said: "We join the Dedagroup Stealth family with great enthusiasm. For us, it is the ideal strategic partner to continue on our ambitious development path. We are truly satisfied with this global operation, which has the clear objective of bringing to the fashion sector an offer that can accompany any brand in every phase of its life, from the launch to the intermediate development phase up to maturity, supporting it in the definition of processes and strategies.”
Mimmo Solida, CEO of Dedagroup Stealth, added: “For too long, many brands have struggled to find an integrated solution that helps them manage their entire supply chain. It has long been our ambition to find a partner that can support designers, small brands and fashion start-ups as they grow, with a range of solutions that support business critical focuses of fashion retailers, from supply chain to sales, that allow for internationalisation. This acquisition will bring new value to the market and, at the same time, will strongly support our expansion strategy geographically and as a business, whilst completing our product portfolio to support fashion brands from entrepreneurial start-ups to enterprise players.”
Marco Podini, Executive Chairman of Dedagroup Stealth parent company Dedagroup, commented:"I am particularly pleased by the acquisition of Zedonk because our software, which has already contributed to the growth of many important creative brands in the world, can help other small fashion companies to develop rapidly. Our support is more vital than ever now that the market has changed so drastically for companies of all sizes, made even worse in the current crisis as whole countries shut down.”
“The global fashion industry needs the right tools to capitalise on business opportunities without being overwhelmed at an organisational level. The tsunami moving from east to west, leaving behind lowered shutters and people locked indoors, will be followed by a second wave that will see everyone wanting to get back to normal. Agility, underpinned by robust digital technologies, will be the catalyst that defines business success and will fuel retail performance in markets as they reopen, starting from China. Dedagroup Stealth will be able to support brands from the very smallest up to the largest as they restart their plans for global expansion,” Podini concluded.
-ENDS-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005645/en/
Contact information
Sarah Cole
Head of PR at Fieldworks Marketing
sarah.cole@fieldworksmarketing.co.uk
07872 884 002
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom